Gary Bedel, MD
Family Medicine · Franklin, OHNPI 1700803780
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,466 of the $15,758 with a category attached, or 79.1%. It is spread thinly across 35 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $9,513 and has fallen 98.7% since, to $119 in 2024. Among family medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $36.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$4K
- Pfizer$2K
- Amgen$2K
- Novo Nordisk$1K
- Johnson & Johnson$946
- AstraZeneca$872
- plus $5K from 29 others
Across 1,088 payments — averaging $729.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$314K
- Novo Nordisk AS$307K
- Kowa Research Institute, Inc.$106K
- Esperion Therapeutics, Inc.$24K
- Janssen Research & Development, LLC$21K
- Ironwood Pharmaceuticals, Inc$12K
- plus $11K from 2 others
What the payments were for
- Travel & lodging$3,29221%
- Food & beverage$12,46679%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 10 | $3,633 |
| Pfizer | 27 | $1,964 |
| Amgen | 32 | $1,893 |
| Novo Nordisk | 64 | $1,423 |
| Johnson & Johnson | 53 | $946 |
| AstraZeneca | 26 | $872 |
| GSK | 8 | $827 |
| AbbVie(2 entities) | 33 | $571 |
| Lilly USA, LLC | 20 | $531 |
| Amarin Pharma, Inc. | 30 | $421 |
| Merck | 21 | $281 |
| Sanofi-aventis U.S. LLC | 13 | $250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $249 |
| Biohaven Pharmaceuticals, Inc. | 6 | $220 |
| Daiichi Sankyo Inc. | 5 | $178 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $177 |
| Boehringer Ingelheim | 4 | $159 |
| Esperion Therapeutics, Inc. | 3 | $156 |
| Teva Pharmaceuticals USA, Inc. | 8 | $144 |
| Bristol Myers Squibb | 1 | $125 |
| Romark Laboratories, LC | 1 | $121 |
| E.r. Squibb & Sons, L.L.C. | 7 | $98 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $89 |
| Novartis | 4 | $71 |
| Biogen | 3 | $54 |
| Abbott | 3 | $54 |
| Kowa Pharmaceuticals America, Inc. | 4 | $51 |
| Antares Pharma, Inc. | 3 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 3 | $38 |
| Mylan Specialty L.p. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVNAR - 13$1,121
- TRELEGY ELLIPTA$599
- EVENITY$567
- Repatha$466
- Alinia$363
- Otezla$233
- Prolia$225
- BREZTRI AEROSPHERE$218
- TRUMENBA$124
- NEXLIZET$123
- NEXLETOL$123
- RYBELSUS$122
- XARELTO$122
- UBRELVY$121
- NURTEC ODT$119
- ABRYSVO$119
- EUCRISA$119
- Wegovy$116
- INJECTAFER$115
- FARXIGA$115
How this compares
$15,758 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $128,574 |
| EliquisApixaban | 34 | $46,583 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $27,448 |
| JardianceEmpagliflozin | 17 | $26,281 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $12,271 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,954 |
| Rosuvastatin Calcium | 216 | $4,606 |
| Esomeprazole Magnesium | 75 | $4,187 |
| Celecoxib | 52 | $3,487 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $3,127 |
| Atorvastatin Calcium | 359 | $3,052 |
| Ezetimibe | 66 | $2,691 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 137 | $2,492 |
| Levothyroxine Sodium | 151 | $1,937 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 17 | $1,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,423 | $128,57488 claims |
| PfizerEliquis | $1,964 | $46,58334 claims |
| Boehringer IngelheimJardiance | $159 | $26,28117 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $827 | $19,22526 claims |
| Sanofi-aventis U.S. LLCLantus | $250 | $1,66811 claims |
| AbbVieSynthroid | $571 | $1,16123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Franklin
- Joshua OrdwayFranklin$166K
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.